David Cohen, MD
Dermatology · Hewlett, NYNPI 1013994839
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,540 of the $27,309 with a category attached, or 60.6%. LEO Pharma Inc. accounts for 64.8% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $19,084, more than ten times the $621 reported in 2019.
Across 698 payments — averaging $39.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LEO Pharma Inc.$18K
- Johnson & Johnson$3K
- AbbVie$2K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$850
- UCB, Inc.$817
- plus $3K from 21 others
What the payments were for
- Consulting fees$16,54061%
- Speaking & faculty fees$1501%
- Food & beverage$10,00437%
- Education$6152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LEO Pharma Inc. | 61 | $17,701 |
| Johnson & Johnson | 158 | $2,578 |
| AbbVie(2 entities) | 112 | $1,675 |
| Novartis | 85 | $1,066 |
| E.r. Squibb & Sons, L.L.C. | 86 | $850 |
| UCB, Inc. | 65 | $817 |
| Lilly USA, LLC | 35 | $669 |
| Dermavant Sciences, Inc. | 31 | $321 |
| Galderma Laboratories, L.p. | 10 | $311 |
| Incyte Corporation | 16 | $269 |
| Dermira, Inc. | 1 | $154 |
| Pfizer | 9 | $146 |
| Cipher Pharmaceuticals US LLC | 1 | $117 |
| AstraZeneca | 1 | $94 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $93 |
| Regeneron Healthcare Solutions, Inc. | 2 | $71 |
| Amgen | 3 | $68 |
| Organon | 3 | $51 |
| Sanofi | 2 | $48 |
| LNHC, Inc | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 2 | $38 |
| Verrica Pharmaceuticals Inc. | 2 | $38 |
| Blueprint Medicines Corporation | 1 | $35 |
| Mylan Pharmaceuticals Inc. | 1 | $18 |
| Almirall LLC | 1 | $14 |
| Mission Pharmacal Company | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,309 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 95 | $1,907,406 |
| Dupixent PenDupilumab | 165 | $620,224 |
| TremfyaGuselkumab | 43 | $577,371 |
| Humira(Cf) PenAdalimumab | 45 | $468,631 |
| Cosentyx Unoready PenSecukinumab | 46 | $376,426 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 49 | $358,880 |
| Taltz AutoinjectorIxekizumab | 16 | $123,760 |
| Dupixent SyringeDupilumab | 29 | $113,358 |
| OpzeluraRuxolitinib Phosphate | 51 | $100,731 |
| CrotanCrotamiton | 47 | $88,242 |
| OtezlaApremilast | 12 | $58,456 |
| VtamaTapinarof | 31 | $43,558 |
| Clindamycin Phosphate | 523 | $42,594 |
| Triamcinolone Acetonide | 1,470 | $35,124 |
| Tacrolimus | 143 | $31,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,578 | $577,37143 claims |
| Incyte CorporationOpzelura | $269 | $100,73151 claims |
| AmgenOtezla | $68 | $58,45612 claims |
| Dermavant Sciences, Inc.Vtama | $321 | $43,55831 claims |
| Dermira, Inc.Qbrexza | $154 | $10,77813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,151 dermatology providers in New York.
Other dermatology in Hewlett
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.